318 completed. 318 Phase 2, 53 Phase 3, 46 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 318 | Completed 318 |
| Phase 3 | 53 | Completed 53 |
| Phase 1 | 46 | Completed 46 |
Follow Insulin Resistance: new trials by email Literature Review of Insulin Resistance trials Research Report on Insulin Resistance
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effect of Topical Insulin on Healing Rate of Pemphigus Lesions insulin glargine, human insulin, 0.9% Normal Saline - Pemphigus Vulgaris, Skin Erosion | Phase 2 | Completed | Alexandria University | 20 | 2024-06-22 | 2026-03-10 |
| Polyamine Treatment in Elderly Patients With Coronary Artery Disease Spermidine, Placebo - Ischemic Heart Disease, Myocardial Infarction | Phase 2 | Completed | University of Aarhus | 187 | 2024-01-01 | 2026-07-01 |
| Study of INV-202 in Patients With Obesity and Metabolic Syndrome INV-202, Placebo - Obesity, Metabolic Syndrome | Phase 2 | Completed | Inversago Pharma Inc. | 243 | 2023-09-08 | 2025-06-05 |
| Vericiguat in Patients With Metabolic Syndrome and Coronary Vascular Dysfunction Vericiguat, Placebo - Metabolic Syndrome, Coronary Microvascular Dysfunction | Phase 2 | Completed | Johns Hopkins University | 45 | 2023-06-16 | 2026-01-27 |
| Study Testing Benefits of Ursolic Acid (UA) as a Countermeasure To Myopenia and Insulin Resistance in Chronic Spinal Cord Injury (SCI) Ursolic Acid, Strength Training - Spinal Cord Injuries, Tetraplegia | Phase 2 | Completed | University of Miami | 10 | 2023-03-27 | 2025-05-21 |
| Everolimus Aging Study Everolimus 0.5 MG once per day, Everolimus 5 MG once per week, Placebo once per day - Aging, Insulin Resistance | Phase 2 | Completed | University of Wisconsin, Madison | 106 | 2023-03-24 | 2026-09-04 |
| The Effects of Glucagon on Hepatic Metabolism Glucagon response study - Obesity, Type2diabetes | Phase 1 / Phase 2 | Completed | Adrian Vella | 21 | 2022-10-20 | 2026-10-14 |
| Weekly Subcutaneous Semaglutide as Adjunct to Closed-loop Therapy in Type 1 Diabetes Care Outpatient therapy: 11 weeks of drug therapy with usual treatment + 4 weeks of closed-loop therapy - Type 1 Diabetes, Diabetes Mellitus, Type 1 | Phase 2 / Phase 3 | Completed | McGill University Health Centre/Research Institute of the McGill University Health Centre | 28 | 2022-10-02 | 2025-01-22 |
| A Pilot Study of Metformin to Reduce Cerebrovascular Dysfunction in Participants With HIV and Metabolic Syndrome. Metformin Extended Release Oral Tablet - Metabolic Syndrome, HIV Seropositivity | Phase 2 | Completed | University of Stellenbosch | 30 | 2022-08-11 | 2025-10-06 |
| Effects of GLP1-RA on Ectopic Fat Deposition in Chronic Kidney Disease dulaglutide injection - Chronic Kidney Diseases | Phase 2 | Completed | Vanderbilt University Medical Center | 7 | 2022-03-15 | 2025-04-20 |
| Home-based Intervention With Semaglutide Treatment Of Neuroleptica-Related Prediabetes Semaglutide, 1.34 mg/mL, Placebo - Schizophrenia, Prediabetic State | Phase 2 | Completed | Jan Frystyk | 154 | 2022-01-01 | 2024-07-08 |
| Colchicine to Suppress Inflammation and Improve Insulin Resistance in Adults and Adolescents With Obesity Colchicine, Placebo - Obesity, Insulin Resistance | Phase 2 | Completed | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | 152 | 2021-11-08 | 2025-09-05 |
| A Proof-of-Activity Study With Orticumab in Subjects With Psoriasis and Cardiometabolic Risk Factors Orticumab, Placebo - Psoriasis, Inflammation | Phase 2 | Completed | Abcentra | 77 | 2021-06-30 | 2026-05-11 |
| eIMPACT-DM Pilot Trial: Depression Treatment to Reduce Diabetes Risk Good Days Ahead (GDA), Problem Solving Treatment in Primary Care (PST-PC), Antidepressant Medications - Depression, Major Depressive Disorder | Phase 2 | Completed | Indiana University | 46 | 2020-10-14 | 2023-11-02 |
| Intranasal Insulin in Parkinson's Disease Regular Novolin R, Placebo - Parkinson Disease | Phase 2 | Completed | HealthPartners Institute | 31 | 2020-02-04 | 2026-02-11 |
| Causal Mechanisms in Adolescent Arterial Stiffness CS+, CS- - Lipid Disorder, Dyslipidemias | Phase 2 | Completed | Baylor College of Medicine | 72 | 2020-02-01 | 2026-11-02 |
| Inositol Supplementation to Treat PCOS (INSUPP-PCOS) Placebo, Inositol - Polycystic Ovary Syndrome, Anovulation | Phase 2 | Completed | Milton S. Hershey Medical Center | 154 | 2020-01-24 | 2026-10-28 |
| The Effect of Intranasal Insulin on Motor and Non-motor Symptoms in Parkinson's Disease Patients Insulin, Normal saline - Parkinson Disease | Phase 2 | Completed | dr.dargahi | 28 | 2020-01-01 | 2024-04-23 |
| Effects of Gum Arabic on Metabolic Syndrome Parameters in Postmenopausal Women Gum Arabic - Metabolic Syndrome in Postmenopausal Females | Phase 2 | Completed | University of Khartoum | 100 | 2019-12-04 | 2026-02-18 |
| Effects of Intranasal Insulin on Neuroimaging Markers and Cognition in Patients With Psychotic Disorders Intranasal Insulin - Psychosis, Schizophrenia | Phase 2 | Completed | Mclean Hospital | 87 | 2019-10-01 | 2026-09-03 |
Showing 20 of 318. Sign in to see all of them.
Metabolic Syndrome (124) · Obesity (60) · Diabetes Mellitus, Type 2 (55) · Diabetes Mellitus (50) · Diabetes Mellitus, Type 1 (34) · Inflammation (20) · Glucose Intolerance (19) · Hypertension (18) · Hypoglycemia (17) · Non-alcoholic Fatty Liver Disease (17) · Overweight (17) · Cardiovascular Diseases (13) · Fatty Liver (13) · Dyslipidemias (11)
Nutritional and Metabolic Diseases (317) · Hyperinsulinism (316) · Glucose Metabolism Disorders (313) · Metabolic Diseases (312) · Endocrine System Diseases (130) · Pathological Conditions, Signs and Symptoms (113) · Signs and Symptoms (88) · Nutrition Disorders (81) · Body Weight (80) · Overnutrition (78) · Diabetes Mellitus (77) · Overweight (61) · Immune System Diseases (40) · Pathologic Processes (40)
Metformin (28) · Insulin (23) · Pioglitazone (14) · Exercise (12) · Cholecalciferol (10) · Rosiglitazone (8) · salicylsalicylic acid (8) · Atorvastatin (6) · Glucagon (6) · Insulin Aspart (6) · Insulin Lispro (6) · Methods (5) · Resveratrol (5) · Vitamin D (5) · recombinant methionyl human leptin (5)
Institut de Recherches Cliniques de Montreal (13) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (10) · University of Guadalajara (10) · Massachusetts General Hospital (6) · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (5) · Joslin Diabetes Center (5) · University of Aarhus (5) · Emory University (4) · Tehran University of Medical Sciences (4) · University of Pennsylvania (4) · University of Toronto (4) · Vanderbilt University Medical Center (4) · Albert Einstein College of Medicine (3) · Bambino Gesù Hospital and Research Institute (3) · Brigham and Women's Hospital (3)
United States (147) · Canada (43) · Germany (14) · Mexico (14) · Denmark (13) · Italy (10) · France (8) · Netherlands (7) · Iran (6) · Sweden (6) · Finland (5) · Switzerland (5) · United Kingdom (5) · Australia (4) · China (4)
Jack A Yanovski, M.D. (5) · Allison B. Goldfine, MD (4) · Raika Jamali, M.D. (4) · Valerio Nobili, MD (3) · Xu Lin, MD, PhD (3) · Alp Ikizler, MD (2) · Andre Marette, PhD (2) · Bahram H. Arjmandi, PhD, RD (2) · Bruno Geloneze, MD, PhD (2) · Christoph Kapitza, MD (2) · Cyndya Shibao, MD (2)
PMID 19889232, PMID 20826632, PMID 21070531, PMID 25091629, PMID 10480510, PMID 10523015, PMID 10868854, PMID 10963727, PMID 11411567, PMID 11443202, PMID 11556815, PMID 12145010, PMID 12523673, PMID 12622244, PMID 15070752, PMID 15168555, PMID 15220351, PMID 15333514, PMID 15713712, PMID 15949871, PMID 16054141, PMID 16157765, PMID 16452557, PMID 16614616, PMID 16626303, PMID 16636217, PMID 16818482, PMID 1695875, PMID 17069794, PMID 17086191, PMID 17112576, PMID 17135615, PMID 17206944, PMID 17245174, PMID 17283239, PMID 17429083, PMID 17517446, PMID 17563345, PMID 17578889, PMID 17682120, PMID 17684509, PMID 17959861, PMID 17986612, PMID 18266981, PMID 18274222, PMID 18460557, PMID 18726828, PMID 18769731, PMID 18854428, PMID 18945255
2009 (2), U01DK074556 (2), UL1RR024150 (2), 1UH3TR001372-01 (1), 2005 (1), 2017 (1), F32DK068902 (1), I01CX000982 (1), K23AG019161 (1), K23HL103976 (1), K23RR023335 (1), KL2RR024151 (1), P30DK019525 (1), P50HL083762 (1), P50HL083813 (1)